Health & FitnessMedicineScienceEducation

GU Cast | Urology Podcast

Professor Declan Murphy & Dr Renu Eapen

A urology podcast, focussing on prostate cancer, kidney cancer, bladder cancer, testis and penile cancer. Join Professor Declan Murphy and Dr Renu Eapen from Peter MacCallum Cancer Centre in Melbourne for this regular dive into the world of genitourinary (GU) Oncology and Urology. Regular guests from all over the world, from every walk of life. Find out more gucast.org

Play

Open in

22 episodes
Avg 30 min
English

Episodes 22

Newest Oldest Longest

All20 Unplayed20 In progress0 Played0

Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.

September 3 · 22 min
PLND for prostate cancer | Yes/No/Maybe?! With Briganti and Maurer
Pelvic lymph node dissection (PLND) - one of our perennial favourite and contentious topics on GU Cast. Today we have both Alberto Briganti (Milano, ITA), and Tobias Maurer (Hamburg, GER), in the studio. Two hugely experienced prostate cancer surgeons, both with huge expertise in PLND. Alberto's name synomous with PLND due to the eponymous nomograms he has deveoped over the years. And Tobias with his pioneering experience in PSMA radio-guided PLND. Your usual hosts are Renu Eapen and Declan Murphy Even better on our YouTube channel
September 1 · 30 min
Journal Club | DETECT haematuria trial and the post-prostatectomy radiotherapy trials
Two great topics on the GU Cast Journal Club today. How should we image patients with haematuria (the DETECT trial, J Urol 2018), and what is the role of adjuvant vs salvage radiotherpay following radical prostatectomy (three great trials - RAVES, RADICALS and GETUG-AFU 17), see links below). Plus we welcome new GU Cast co-Editor Gaetan Devos, who recently joined us on Fellowship at Peter Mac, replacing Carlos Delgado. Usual GU Cast Hosts are Renu Eapen and Declan Murphy, and GU Cast Journal Club Editor, Elena Berg. Links: 1. Can Renal and Bladder Ultrasound Replace Computerized Tomography Urogram in Patients Investigated for Microscopic Hematuria? 2. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial 3. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial 4. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial
August 20 · 45 min
Widespread welcome for new Aussie prostate cancer guidelines
The perennially thorny topic of prostate cancer screening has been very well addressed in the brand new Australian guidelines for the Early Detection of Prostate Cancer which we are delighted to highlight today. Pragmatic, progressive and patient-focused, are some of the comments we have read - great to hear! We have been very gratified to see the very positive reception which these guidelines have received, not just here in Australia, but also by other expert and patient groups around the world. Today, GU Cast co-Host Declan Murphy (also a member of the Guideline Expert Advisory Group), chat with co-Chair of the Guideline committee, Prof Peter Heathcote (Urologist, ex-president of USANZ), and Dr. Jane Crowe (GP, co-Chair of the PSA Working Group along with Declan). What are the key messages for men in different age groups? Which men are considered higher risk? What are the major changes from the old guideline? All this and more in this episode of GU Cast. See below for links to all the key documents, and huge congratulations to Guideline co-Chair Jeff Dunn and all at the Prostate Cancer Foundation of Australia for enabling this, and everyone involved in the process. Too many to mention! Links: https://www.pcfa.org.au/awareness/new-guidelines-for-the-early-detection-of-prostate-cancer/
August 9 · 42 min
Advanced prostate cancer in a large urology group practice
Urologist Ben Lowentritt (Chesapeake Urology, Baltimore), pops into the studio today while passing through Melbourne. We chat about life in a large urology group practice (a huge part of urology service delivery in the USA), why there appears to be a drop in interest in Fellowship training, and his experience of managing advanced prostate cancer in a large urology group practice. Ben, who is also Secretary of the Large Urology Group Practice Association in the USA, has a lot of interest in gathering real world data from large urology group practices, and shares with us some data on the use of ARPIs in mHSPC which has recently been accepted for publication. This is a Themed Podcast supported by our Gold Partners, Johnson & Johnson.
July 24 · 40 min
Journal Club | Randomised surgical trials that did not change practice!
Open vs partial nephrectomy, and open vs robotic prostatectomy - two large randomised trials that did not change surgical practice! Just as important to examine these in GU Cast Journal Club as to examine pivotal trials that did change practice. Today we discuss the EORTC Today we discuss the EORTC 30904 RCT looking at kidney cancer surgery (Eur Urol 2011), and the Brisbane randomised trial of open vs robotic prostatectomy conducted (Lancet 2016). We are delighted to welcome back our GU Cast Journal Club Editors, Dr Carlos Delgado (Mexico City, MEX), and Dr Elena Berg (Munich, GER), along with main GU Cast Hosts, Renu Eapen and Declan Murphy. AN emotional one as Carlos is heading home to Mexico soon! Links to papers below: 1. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma Eur Urol 2011 2. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: early outcomes from a randomised controlled phase 3 study Lancet 2016 Even better on our YouTube channel About GU Cast Journal Club: Each month, two papers are discussed, each of which are of importance to the GU Oncology community. These may be recent papers, or occasionally we will chose a classic landmark paper in GU Oncology . The objective is to draw attention to important papers in GU Oncology, and critique these in a robust manner . The key target audience is trainees working in Urology, Medical Oncology, Radiation Oncology, Nuclear Medicine, and diagnostic specialties such as Radiology and Pathology. But any of our regular audience are likely to enjoy this Journal Club series.
July 15 · 26 min
ARASEC - Rethinking clinical trial design
Welcome back Rana McKay! Renu was on a flight to Europe this week so Rana jumped into her seat in the GU Cast studio this week to have a chat about the intriguing ARASEC trial which she presented at the AUA Annual Meeting recently. Plus her thoughts on the ARACOG data presented at ASCO last month. And then a great chat with our other studio guest, Professor Renea Taylor, translational scientist at Peter Mac and Monash University, about the very interesting Early Onset Prostate Cancer project, an international collaboration which herself and Rana are both very involved with, looking at the reasons behind why younger men are turning up with aggressive prostate cancer. This is a Themed Podcast supported by our Gold Partners, Bayer Pharmaceuticals. Even better on our YouTube channel Links: ARASEC trial at AUA 2026 ARACOG trial at ASCO 2026
July 12 · 29 min
Timing, touch & technique: Batting lessons for nerve-sparing radical prostatectomy | With Ash Tewari
Tips and tricks for nerve-sparing surgery, learned over 25 years of performing robotic radical prostatectomy. Today we are joined by Dr Ash Tewari, Chief of Urology at Mt Sinai (New York), to talk about his favourite topic - nerve-sparing surgery - and a little about his second favourite topic - cricket! Ash has been one of the world's foremost experts in robotic prostatectomy having been there at the very start when Mani Menon was developing the technique, and has studied the anatomy of nerve-sparing prostatectomy in fine detail. Today we chat through his thoughts on the optimal approach to nerve-sparing prostatectomy to deliver the best outcomes for our patients. Some surgical footage included on the YouTube version. This is a Themed Podcast supported by our Silver Partner, Device Technologies. Links: 7th International Prostate Cancer Symposium December 2025 - Lecture on nerve-sparing surgery Mt Sinai Symposium at AUA, May 2026 - Lecture on nerve-sparing surgery
June 29 · 32 min
Berlin Masterclass | Advanced prostate cancer
Hot topics in a hot city!! Declan and Renu escaped from deep Winter in Melbourne and landed into the hottest day on record in Berlin!! We are here to help with the Astellas Global Prostate Cancer Masterclass, a wonderful two day meeting focussing on advanced prostate cancer. Delegates from all over the world and a top class local and International faculty. We catch up with great friends of GU Cast Stephen Freedland (Cedars-Sinai Medical Centre, Los Angeles) and Bertrand Tombal (UC Louvain, Brussels), to pick their brains on hot topics in this hot city. This is a Themed Podcast supported by our Platinum Partner, Astellas. Even better on our YouTube channel
June 24 · 32 min
EV-pembro in localised and advanced bladder cancer - a superb summary!
All you need to know about enfortumab vedotin (EV) & pembro in bladder cancer in 25 minutes! We are joined in studio by bladder cancer gurus Shilpa Gupta (Cleveland Clinic, USA) and Andrew Weickhardt (Austin Health, AUS) to get an update on the role of EV-pembro in both muscle-invasive localised bladder cancer, and metastatic bladder cancer. Shilpa led a very nice paper in this month's European Urology titled optimal management of muscle, invasive bladder, cancer, so we were very keen to pick her brains on this, especially the emerging role of peri-operative EV-pembro. We also picked herself and Andrew‘s brains for the optimal management of metastatic bladder cancer, as they were both involved in the historic EV 302 trial which has transformed the management of metastatic bladder cancer. Must know stuff! A great overview of where we stand today. Thanks so much to Shilpa for dropping into Gu Cast while on holidays in Australia! With your usual hosts are Declan Murphy and Reno Eapn This is a Themed Podcast, supported by our Platinum Partners, Astellas Disclaimer: Enfortumab vedotin in combination with pembrolizumab is not registered for MIBC in Australia and a number of other countries. Please refer to the registration status in your country before prescribing Links: Eur Urol paper on optimal management of MIBC
June 20 · 24 min
Testis cancer and miR-371 - all you need to know!
Yep it's been a buzz word in testis cancer for a while now, but with the read-out of the CLIMATE and SWOG 1823 trials in the past six months, we thought we better get ourselves updated on this exciting biomarker. We are joined in studio by testis cancer gurus Ben Tran (Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne), and online by Aditya Bagrodia (Urologist, UCSD, San Diego), to give us a bluffers guide to miR-371. Plus we hear about the fantastic MaGIC Consortium global testis cancer meeting which takes place in Melbourne 8-11 January 2027. See links below. A great excuse to come to Melbourne, especially to escape the Northern Hemisphere winter! Links: MaGIC Consortium Conference, January 2027 Some coverage of the ANZUP CLIMATE trial from ASCO GU 2026 Some coverage of the SWOG 1823 trial from ASCO 2026
June 13 · 22 min
Journal club #8 | PROTECT and EV-301
Welcome to Episode 8 of our monthly GU Cast Journal Club! Today we focus on two very important papers in localised prostate cancer and metastatic bladder cancer. The landmark 15 year update of the PROTECT trial, published in NEJM in 2023, and the breakthrough EV-301 trial which heralded enfortumab vedotin in progressive metastatic bladder cancer, published in NEJM in 2021. We are delighted to welcome back our GU Cast Journal Club Editors, Dr Carlos Delgado (Mexico City, MEX), and Dr Elena Berg (Munich, GER), along with main GU Cast Hosts, Renu Eapen and Declan Murphy. Links to papers below: 1. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer NEJM 2023 2. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma NEJM 2021 Even better on our YouTube channel About GU Cast Journal Club: Each month, two papers are discussed, each of which are of importance to the GU Oncology community. These may be recent papers, or occasionally we will chose a classic landmark paper in GU Oncology . The objective is to draw attention to important papers in GU Oncology, and critique these in a robust manner . The key target audience is trainees working in Urology, Medical Oncology, Radiation Oncology, Nuclear Medicine, and diagnostic specialties such as Radiology and Pathology. But any of our regular audience are likely to enjoy this Journal Club series.
June 9 · 25 min
Bayer Apex comes to Melbourne!
Renu had been to an excellent Bayer Apex meeting in Europe in the past, so was very happy to hear Apex was coming to us for its first Asia-Pacific outing! A wonderful prostate cancer Faculty headlined by Neal Shore, Dan George, Derya Tilki, Fred Saad, Amit Bahl, Tamim Niazi to name but a few, plus almost 200 delegates from across the APAC region. Your usual hosts Renu Eapen and Declan Murphy catch up with some of the speakers and bring you conference highlights. This is a Themed Podcast, supported by our Gold Partner, Bayer Pharmaceuticals.
May 31 · 39 min
Did PROTEUS just change Urology??
Breaking News podcast just after the long-awaited PROTEUS trial reads out at the ASCO Plenary in Chicago! Plus a simultaneous NEJM paper! Huge day for prostate cancer surgery. Declan and Renu are joined by lead author Dr Mary-Ellen Taplin (Dana Farber Cancer Institute & Harvard University), to tell us about her decades long journey to this huge moment today. PROTEUS is a huge (2,100 men) phase III RCT of men undergoing radical prostatectomy for high-risk prostate cancer, randomised to receive peri-operative ADT + placebo, or ADT plus apalutamide. Mary-Ellen talks to us about the top-line results, and we consider whether this is truly a practice-changing study. Declan also had the honour of being the Discussant at teh ASCO Plenary so he is well placed to give his opinion. Your usual hosts are Declan Murphy & Renu Eapen. Even better on our YouTube channel This is a Themed Podcast supported by our Gold Partner, Johnson & Johnson. Links: PROTEUS NEJM paper
May 17 · 32 min
ARASEC and Lead-in ADT - China focus
Two interesting papers caught the eye of our GU Cast China team this week; the first is the ARASEC trial which Dr Rana McKay read out in the Practice-Changing Plenary at the AUA Annual Meeting in Washington. This is an interesting comparison of ADT + darolutamide for mHSPC in a prospective US cohort, compared with an historical ADT-only control arm from CHAARTED. Interesting study design and interesting results. The second is the ADT Lead-In study led bu GU Cast China Editor, Dr Yao Zhu, which demonstrates how the timing of docetaxel chemotherapy in mHSPC can significnatly affect the likelihood of severe neutropenia. Your usual hosts, Declan Murphy and Renu Eapen, anre joined by Dr Yao Zhu (Fudan University, Shanghai), Dr Yige Bau (SCU Xiamen), and Dr Chuguan Yang (Tonji Hospital, Wuhan). Yige now also part of our GU Cast China team, looking after our We Chat content with Yao Zhu. This is a Themed Podcast supported by our GU Cast China Partner, Bayer Pharmaceuticals.
April 23 · 27 min
Is Copper the new Gold??! Co-PSMA trial in European Urology
Now this is an interesting one, a new PSMA tracer which appears to greatly outperform 68Ga-PSMA-11 for biochemical recurrence. We discuss 64Cu-SAR-bisPSMA with Professor Louise Emmett (Nuclear Medicine Physician, Sydney), and Dr Matt Roberts (Urologist, Brisbane), which they compared head to head with trusty old 68Ga-PSMA-11 in the Co-PSMA trial, just published in European Urology. With usual hosts Declan Murphy and Renu Eapen. This Themed Podcast is supported by our new Bronze Partners, Clarity Pharmaceuticals Even better on our YouTube channel Links: Co-PSMA trial in European Urology Clarity Pharmaceuticals website
April 12 · 28 min
EAU Prostate Cancer Guideline Update
One of our most popular podcasts every year is when we chat with EAU Guideline gurus Derya Tilki and Gianluca Giannarini about the latest updates to the EAU Prostate Cancer Guideline. It is a 250 word document which is updated in March every year and changes are eagerly awaited around the world. We catch up with Derya (Vice Chair of the Prostate Cancer Guidleine Committee) in person in Melbourne, and with Gianluca (Vice-Chair of the EAU Guideline Office) online, about the latest updates. We also chat with Gianluca about the work of the Guideline Dissemination Committee which he has Chaired for a number of years. With usual hosts Renu Eapen and Declan Murphy. Supported by our Gold Partners, Bayer Pharmaceuticals.
April 6 · 28 min
Journal club #7 | proPSMA and Penile Fractures(!)
Democracy in action! This month's GU Cast Journal Club papers were chosen by an audience vote at our GU Cast Live Event at EAU in London. Therefore today we focus on first, the landmark proPSMA paper which established the superior accuracy of PSMA PET/CT for staging unfavourable intermediate and high-risk prostate cancer (Lancet 2020). Then for something completely different, we dig out a paper called "Penile fractures - the merry price of Christmas", published in BJUI 2020. Thanks very much to our live audience for this one! We are delighted to welcome back our GU Cast Journal Club Editors, Dr Carlos Delgado and Dr Elena Berg who joins us in studio for the first time. Elena has just moved to Melbourne to join Carlos doing a Fellowship with GU Cast hosts, Renu Eapen and Declan Murphy. Links to papers below: 1. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020 2. Penile fractures: the price of a Merry Christmas BJUI 2023 GU Cast Journal Club is supported by our Partner, MSD, through an unrestricted educational grant. Even better on our YouTube channel About GU Cast Journal Club: Each month, two papers are discussed, each of which are of importance to the GU Oncology community. These may be recent papers, or occasionally we will chose a classic landmark paper in GU Oncology . The objective is to draw attention to important papers in GU Oncology, and critique these in a robust manner . The key target audience is trainees working in Urology, Medical Oncology, Radiation Oncology, Nuclear Medicine, and diagnostic specialties such as Radiology and Pathology. But any of our regular audience are likely to enjoy this Journal Club series.
April 2 · 25 min
ASPIRE-ing to answer the Triplet question! With Rana McKay and Deepak Kilari
The trial they said would never be done! Huge congrats to the Alliance for Clinical Trials in Oncology who have recently opened the ASPIRE trial, a phase III randomised trial of ADT + apalutamide (doublet), vs ADT + apalutamide + docetaxel chemotherapy (triplet) for men with mHSPC. 1200 men will be recruited from more than 300 sites across the US with many sites already open and recruiting. This is the key trial which will answer the question of whether there is an overall survival benefit of adding chemo to the ADT/ARPI doublet which we all agree is standard of care. We chat with study chair Dr Deepak Kilari (Medical College of Wisconsin) and Dr Rana McKay (University of California San Diego), and learn all about the rationale for ASPIRE, the study design, and the novel genomic stratification factors. Your usual hosts are Renu Eapen and (chemo-sceptic) Declan Murphy! This is a Themed Podcast supported by our Gold Partners, Johnson & Johnson Pharmaceuticals. Links: Alliance website with study details Urology Times coverage Clinical Trials registration
March 20 · 41 min
From Studio to Stage: GU Cast Live at EAU in London!
Our biggest live show to date! Taking to the huge eUro 2 auditorium at this month's EAU Annual Meeting in London, Declan and Renu bring you a fast-paced, high-energy session packed with favourite guests, controversial topics, behind-the-scenes stories, and lots of great giveaways, all boosted by having hundreds of our loyal supporters there in the audience with us. Huge thanks to Maarten Albersen and all at the EAU Scientific Office for this invitation, and to everyone at MediAVentures, M-Events, Congress Consultants, Soma Studios and CMDM Media for helping us put it together. And to our own team including David Chen, Carlos Delgado, and Elena Berg for their help and for being with us in London. This one for sure best enjoyed on our YouTube channel
March 13 · 33 min
PRIMARY 2 is positive! PSMA PET/CT moves to early detection
Big day at the EAU Annual Meeting n London today, as our colleague Dr James Buteau (Nuclear Medicine Physician, Peter MacCallum Cancer Centre, Melbourne), reads out the PRIMARY 2 RCT at the Practice-Changing Plenary in London. Plus a simultaneous publication in Lancet Oncology. Big news for the early detection of prostate cancer, especially for patients with normal or equivocal MRI scans. Declan Murphy and Renu Eapen are joined by James and senior author, Prof Louise Emmett (St Vincent's Hospital, Sydney), to discuss the journey from our first PSMA PET/CT scans in 2014, to the proPSMA trial, the PRIMARY trial, and now the PRIMARY 2 RCT. We discuss why this should now mean that patients with a PIRADS 2 or 3 prostate MRI, and a persisting suspicion such as high PSA density, should be considered for a PSMA PET/CT, rather than a systematic biopsy. Huge congratulations to all the investigators across Australia for seeing this trial through to successful completion, and to all the patients who participated. Acknowledgements: Sponsored by Peter MacCallum Cancer Centre, with financial support from the Prostate Cancer Foundation (PCF), St Vincent’s Curran Foundation, ProsTIC, Peter Mac Foundation, NHMRC and ANZUP Links: PRIMARY 2 trial in Lancet Oncology

Showing 1–20 of 22 episodes